Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Mar;42(3):721-4.
doi: 10.1128/AAC.42.3.721.

Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium

M J Rybak  1 , D M Cappelletty, T Moldovan, J R Aeschlimann, G W Kaatz
Affiliations
Comparative Study

Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium

M J Rybak et al. Antimicrob Agents Chemother. 1998 Mar.

Abstract

The activities of the oxazolidinone antibacterial agents eperezolid (PNU-100592) and linezolid (PNU-100766) were compared with that of vancomycin against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus (n = 200), coagulase-negative staphylococci (n = 100), and vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium (n = 50). Eperezolid and linezolid demonstrated good in vitro inhibitory activity, regardless of methicillin susceptibility for staphylococci (MIC at which 90% of the isolates are inhibited [MIC90] range, 1 to 4 microg/ml) or vancomycin susceptibility for enterococci (MIC90 range, 1 to 4 microg/ml). In time-kill studies, eperezolid and linezolid were bacteriostatic in action. A postantibiotic effect of 0.8+/-0.5 h was demonstrated for both eperezolid and linezolid against S. aureus, S. epidermidis, E. faecalis, and E. faecium.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Time-kill experiments performed in duplicate. Results are means ± standard deviations. (A and B) Methicillin-resistant S. aureus (R323) and methicillin-susceptible S. epidermidis (R264), respectively. (C and D) Vancomycin (Vanco)-resistant E. faecalis (R581) and E. faecium (R20), respectively.
See this image and copyright information in PMC

References

    1. Barry A L. In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents. Antimicrob Agents Chemother. 1988;32:150–152. - PMC - PubMed
    1. Brumfitt W, Hamilton-Miller J M T. Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709. Diagn Microbiol Infect Dis. 1992;15:621–624. - PubMed
    1. Craig W A, Gudmundsson S. Postantibiotic effect. In: Lorian V, editor. Antibiotics in laboratory medicine. 3rd ed. Baltimore, Md: The Williams & Wilkins Co.; 1991. pp. 403–431.
    1. Daly J S, Eliopolous G M, Reiszner E, Moellering R C., Jr Mechanism of action and activity of DuP 105 and DuP 721, new oxazolidinone compounds. J Antimicrob Chemother. 1988;21:721–730. - PubMed
    1. Daly J S, Eliopolous G M, Willey S, Moellering R C., Jr Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 1988;32:1341–1346. - PMC - PubMed

Publication types